Skip to main content

Table 2 Patient Characteristics

From: Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group

Study and Treatment Arm Mean Age at Enrollmenta Patient Sexb Total Expected Weeks Dexc Doxorubicin Trastuzumab
Male Female
AOST0121 AOST0121 HER2 Negative 15.1 (3.6) 33 (60.0%) 22 (40.0%) 55 (100%) 34 3.75 g/m2 375 mg/m2 70 mg/kg
AOST0121 HER2 Positive 13.7 (2.7) 19 (47.5%) 21 (52.5%) 40 (100%) 34 3.75 g/m2 375 mg/m2  
P9754 P9754 Pilot 1 Good Response 13.5 (5.0) 16 (47.1%) 18 (52.9%) 34 (100%) 28 4.5 g/m2 450 mg/m2  
P9754 Pilot 1 Standard Response 13.9 (4.4) 48 (62.3%) 29 (37.7%) 77 (100%) 29 6 g/m2 600 mg/m2  
P9754 Pilot 2 Good Response 13.9 (3.9) 7 (33.3%) 14 (66.7%) 21 (100%) 28 4.5 g/m2 450 mg/m2  
P9754 Pilot 2 Standard Response 13.8 (4.5) 20 (60.6%) 13 (39.4%) 33 (100%) 31 6 g/m2 600 mg/m2  
P9754 Pilot 3 Good Response 14.3 (4.0) 12 (63.2%) 7 (36.8%) 19 (100%) 28 4.5 g/m2 450 mg/m2  
P9754 Pilot 3 Standard Response 13.4 (4.6) 20 (54.1%) 17 (45.9%) 37 (100%) 36 4.5 g/m2 450 mg/m2  
  1. aMean (SD), years
  2. bNumber (%)
  3. cDex, Dexrazoxane